In a commentary for Nutritional Outlook, Scott Mazza reviews 2023 as a year of regulatory stagnation but meaningful scientific and social progress for CBD, highlighting the delayed Farm Bill update, ongoing uncertainty around delta-8 THC, and FDA hesitation on CBD as a dietary supplement. He outlines key research milestones from the year, including emerging evidence on CBD’s role in opioid use disorder, dosage safety thresholds, hair loss, and other health conditions that continue to reshape the compound’s scientific credibility. Mazza concludes that declining social stigma and growing consumer adoption position CBD for further maturation in 2024, provided policymakers deliver clearer regulatory guidance and enforceable production standards.